Apalutamide Makes Its Case in Biochemically Recurrent Nonmetastatic Prostate Cancer
A 1-year period of intensified androgen receptor blockade prolonged prostate-specific antigen progression-free survival (PSA-PFS) compared with androgen deprivation therapy (ADT) alone for patients with high-risk, biochemically recurrent prostate cancer, according to interim results from a phase III trial. In the three-arm PRESTO study, adding either apalutamide (Erleada) or apalutamide plus abiraterone acetate (Zytiga) and prednisone […]
More Evidence Linking ADT for Prostate Cancer to Adverse Neurocognitive Effects
Men treated with androgen deprivation therapy (ADT) for prostate cancer had a significantly higher risk of dementia and other neurocognitive disorders, according to a meta-analysis of more than 2.5 million patients. The magnitude of excess risk ranged from 20% for dementia to 66% for depression. The risk of Alzheimer’s disease, vascular dementia, and Parkinson’s disease […]
FDA Approves Fixed-Dose Prostate Cancer Combination Treatment
The FDA approved the first fixed-dose combination of the PARP inhibitor niraparib and the androgen biosynthesis inhibitor abiraterone (Akeega) for metastatic BRCA-mutant castration-resistant prostate cancer (CRPC). The approval stipulates use of the dual-action tablet with prednisone in patients with metastatic BRCA-mutant CRPC confirmed by an FDA-approved diagnostic test. Eligible patients must have had prior bilateral […]
Another Online SARMs Retailer Gets a Warning From the FDA
The FDA issued a warning letter to an online retailer selling multiple selective androgen receptor modulators (SARMs) earlier this month, in an ongoing effort to curb their use in consumers, the agency said. This recent letter advised a California-based company, known as Warrior Labz SARMS, and its owner, Jeremy Brown, to stop actively marketing SARMs […]
Enzalutamide-ADT Cuts Risk for Disease Spread in Nonmetastatic Prostate Cancer
CHICAGO — Combining enzalutamide (Xtandi) with an androgen deprivation therapy (ADT) boosted metastasis-free survival (MFS) in patients with prostate cancer at high risk for biochemical recurrence, according to the EMBARK trial. After a median follow up of 60.7 months, the combination of enzalutamide and leuprolide acetate ADT demonstrated a 58% reduction in the risk of […]
Escalated ADT Falls Short in Men With High-Risk Features After Prostatectomy
SAN FRANCISCO — Add-on hormone therapy plus an antiandrogen to salvage radiation and androgen deprivation therapy (ADT) did not boost survival outcomes in high-risk prostate cancer. In the FORMULA-509 trial, the addition of 6 months of abiraterone acetate (Zytiga) and apalutamide (Erleada) to salvage radiation (RT) and 6 months of ADT with a GnRH agonist […]
Long-Term ADT With Radiation Helps Prevent Post-Prostatectomy Metastases
PARIS — In men undergoing radiotherapy after radical prostatectomy, 2 years of androgen deprivation therapy (ADT) improved outcomes when compared with a shorter course of ADT, according to results from the RADICALS-HD trial. At a median follow-up of more than 9 years, investigators found that the longer ADT duration improved metastasis-free survival (MFS) compared with […]
Rezvilutamide Bests Bicalutamide in Metastatic Prostate Cancer
In combination with androgen deprivation therapy (ADT), the novel androgen-receptor inhibitor rezvilutamide significantly improved radiographic progression-free survival (PFS) and overall survival (OS) compared with bicalutamide (Casodex) in patients with high-volume, metastatic, hormone-sensitive prostate cancer, the phase III CHART trial showed. Among 654 mostly Asian patients, median radiographic PFS was not reached in the rezvilutamide group […]
End of the Line for a Failed Prostate Cancer Drug
The androgen synthesis inhibitor orteronel failed to improve survival in metastatic hormone-sensitive prostate cancer (mHSPC) despite a twofold improvement in progression-free survival (PFS) versus standard androgen-deprivation therapy (ADT), a large randomized trial showed. Patients randomized to ADT plus orteronel had a median overall survival (OS) of 81 months compared with 70.2 months with ADT plus […]
For Men on ADT, Checking Bone Density May Thwart Fractures
Bone density testing in older prostate cancer patients on androgen deprivation therapy (ADT) was significantly associated with a decreased risk for major osteoporotic fractures, but remains little used, a prospective population-based study found. In the cohort of nearly 55,000 men treated with ADT from 2005 to 2015, those who received dual x-ray absorptiometry (DXA) screening […]